Novo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight ...

As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for ...

Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover ...

Discover why Novo Nordisk A/S' undervalued shares present a buying opportunity, with strong sales growth, profitability, and ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

By Patrick Wingrove and Maggie Fick (Reuters) -As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

U.S.-listed shares of Novo Nordisk declined in premarket trading Friday on the surprise news that CEO Lars Fruergaard ...

Novo Nordisk (NYSE: NVO) stock jumped 3% through ... despite tightened FDA regulations on compounders, now that Wegovy production is sufficient to meet demand. It might also mollify Novo such ...

Novo Nordisk A/S' CEO transition sparks governance concerns, but internal succession ensures stability. Click for my updated ...

After the the FDA declared an end to the shortage of GLP-1 medications, compounded versions of the drug must be out of the market by Thursday.